Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

This RCT of 3216 men followed up over 62 months, showed hypofractionated radiotherapy (60Gy in 20 fractions) is non-inferior to conventional fractionation (74Gy in 37 fractions) and is recommended as a standard of care for external-beam radiotherapy of localised prostate cancer.

This is one of two studies published in this edition which evaluates hypofractionated radiotherapy.

 

In a related editorial, the author highlights that NRG Oncology trial investigators have previously noted a slight increase in clinician-reported grade 2 gastrointestinal and genitourinary toxic effects, and clinicians might use this as justification to not adopt this particular hypofractionation schedule, particularly in patients with large prostates or clinically significant pre-existing urinary dysfunction. Therefore, future ancillary analyses of the NRG Oncology study will define the appropriate dose constraints to keep grade 2 gastrointestinal and genitourinary toxic effects low.